Analysis of the antibody response to immunization with purified O‐acetyl GD3 gangliosides in patients with malignant melanoma

Gerd Ritter, Erika Ritter‐Boosfeld, Rita Adluri, Michele Calves, Shunlin Ren, Robert K Yu, Herbert F. Oettgen, Lloyd J. Old, Philip O. Livingston

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Gangliosides expressed in malignant melanoma are potential targets for immunotherapy. Immunization of melanoma patients with vaccines containing purified GM2 ganglioside has resulted in induction of GM2 antibodies, and high titers of GM2 antibodies have correlated with increased survival. Melanoma ganglioside 9‐O‐acetyl GD3 is another candidate for ganglioside vaccine construction because of its limited expression in normal human tissues. As purification of 9‐O‐acetyl GD3 from human melanoma (9‐O‐acetylated on the terminal sialic acid) is not practical for broad application, we investigated the antibody response of melanoma patients to O‐acetyl GD3 from several additional sources: hamster melanoma (7‐O‐acetyl GO3), bovine buttermilk (mixture of 7‐O‐acetyl GD3, 9‐O‐acetyl GD3 and 7,9‐di‐O‐acetyl GD3) and chemically modified GD3 from bovine brain (9‐O‐acetylated on the subterminal sialic acid). Only immunization with the buttermilk‐derived O‐acetyl GD3 preparation resulted in consistent production of IgM antibodies. However, the induced antibodies reacted with the immunogen and with 7‐O‐acetyl GO3 derived from hamster melanoma but not with 9‐O‐acetyl GD3 or human melanoma cells expressing 9‐O‐acetyl GD3 on their cell surface. In contrast, all O‐acetyl GD3 derivatives used for immunization were recognized by murine MAbs that reacted with 9‐O‐acetyl GD3, and immunization of mice with buttermilk‐derived O‐acetyl GD3 resulted in the production of antibodies that reacted with human melanoma cells expressing 9‐O‐acetyl GD3. Apparently, the human and murine immune systems preferentially recognize different epitopes on these molecules. © 1995 Wiley‐Liss, Inc.

Original languageEnglish (US)
Pages (from-to)668-672
Number of pages5
JournalInternational Journal of Cancer
Volume62
Issue number6
DOIs
StatePublished - Jan 1 1995
Externally publishedYes

Fingerprint

Antibody Formation
Melanoma
Immunization
Gangliosides
N-Acetylneuraminic Acid
Cricetinae
Antibodies
Vaccines
G(M2) Ganglioside
GD3 ganglioside
Immunotherapy
Immunoglobulin M
Epitopes
Immune System
Survival
Brain

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Analysis of the antibody response to immunization with purified O‐acetyl GD3 gangliosides in patients with malignant melanoma. / Ritter, Gerd; Ritter‐Boosfeld, Erika; Adluri, Rita; Calves, Michele; Ren, Shunlin; Yu, Robert K; Oettgen, Herbert F.; Old, Lloyd J.; Livingston, Philip O.

In: International Journal of Cancer, Vol. 62, No. 6, 01.01.1995, p. 668-672.

Research output: Contribution to journalArticle

Ritter, G, Ritter‐Boosfeld, E, Adluri, R, Calves, M, Ren, S, Yu, RK, Oettgen, HF, Old, LJ & Livingston, PO 1995, 'Analysis of the antibody response to immunization with purified O‐acetyl GD3 gangliosides in patients with malignant melanoma', International Journal of Cancer, vol. 62, no. 6, pp. 668-672. https://doi.org/10.1002/ijc.2910620604
Ritter, Gerd ; Ritter‐Boosfeld, Erika ; Adluri, Rita ; Calves, Michele ; Ren, Shunlin ; Yu, Robert K ; Oettgen, Herbert F. ; Old, Lloyd J. ; Livingston, Philip O. / Analysis of the antibody response to immunization with purified O‐acetyl GD3 gangliosides in patients with malignant melanoma. In: International Journal of Cancer. 1995 ; Vol. 62, No. 6. pp. 668-672.
@article{4a84064a064e4cb08637ec7c9c373df7,
title = "Analysis of the antibody response to immunization with purified O‐acetyl GD3 gangliosides in patients with malignant melanoma",
abstract = "Gangliosides expressed in malignant melanoma are potential targets for immunotherapy. Immunization of melanoma patients with vaccines containing purified GM2 ganglioside has resulted in induction of GM2 antibodies, and high titers of GM2 antibodies have correlated with increased survival. Melanoma ganglioside 9‐O‐acetyl GD3 is another candidate for ganglioside vaccine construction because of its limited expression in normal human tissues. As purification of 9‐O‐acetyl GD3 from human melanoma (9‐O‐acetylated on the terminal sialic acid) is not practical for broad application, we investigated the antibody response of melanoma patients to O‐acetyl GD3 from several additional sources: hamster melanoma (7‐O‐acetyl GO3), bovine buttermilk (mixture of 7‐O‐acetyl GD3, 9‐O‐acetyl GD3 and 7,9‐di‐O‐acetyl GD3) and chemically modified GD3 from bovine brain (9‐O‐acetylated on the subterminal sialic acid). Only immunization with the buttermilk‐derived O‐acetyl GD3 preparation resulted in consistent production of IgM antibodies. However, the induced antibodies reacted with the immunogen and with 7‐O‐acetyl GO3 derived from hamster melanoma but not with 9‐O‐acetyl GD3 or human melanoma cells expressing 9‐O‐acetyl GD3 on their cell surface. In contrast, all O‐acetyl GD3 derivatives used for immunization were recognized by murine MAbs that reacted with 9‐O‐acetyl GD3, and immunization of mice with buttermilk‐derived O‐acetyl GD3 resulted in the production of antibodies that reacted with human melanoma cells expressing 9‐O‐acetyl GD3. Apparently, the human and murine immune systems preferentially recognize different epitopes on these molecules. {\circledC} 1995 Wiley‐Liss, Inc.",
author = "Gerd Ritter and Erika Ritter‐Boosfeld and Rita Adluri and Michele Calves and Shunlin Ren and Yu, {Robert K} and Oettgen, {Herbert F.} and Old, {Lloyd J.} and Livingston, {Philip O.}",
year = "1995",
month = "1",
day = "1",
doi = "10.1002/ijc.2910620604",
language = "English (US)",
volume = "62",
pages = "668--672",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Analysis of the antibody response to immunization with purified O‐acetyl GD3 gangliosides in patients with malignant melanoma

AU - Ritter, Gerd

AU - Ritter‐Boosfeld, Erika

AU - Adluri, Rita

AU - Calves, Michele

AU - Ren, Shunlin

AU - Yu, Robert K

AU - Oettgen, Herbert F.

AU - Old, Lloyd J.

AU - Livingston, Philip O.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Gangliosides expressed in malignant melanoma are potential targets for immunotherapy. Immunization of melanoma patients with vaccines containing purified GM2 ganglioside has resulted in induction of GM2 antibodies, and high titers of GM2 antibodies have correlated with increased survival. Melanoma ganglioside 9‐O‐acetyl GD3 is another candidate for ganglioside vaccine construction because of its limited expression in normal human tissues. As purification of 9‐O‐acetyl GD3 from human melanoma (9‐O‐acetylated on the terminal sialic acid) is not practical for broad application, we investigated the antibody response of melanoma patients to O‐acetyl GD3 from several additional sources: hamster melanoma (7‐O‐acetyl GO3), bovine buttermilk (mixture of 7‐O‐acetyl GD3, 9‐O‐acetyl GD3 and 7,9‐di‐O‐acetyl GD3) and chemically modified GD3 from bovine brain (9‐O‐acetylated on the subterminal sialic acid). Only immunization with the buttermilk‐derived O‐acetyl GD3 preparation resulted in consistent production of IgM antibodies. However, the induced antibodies reacted with the immunogen and with 7‐O‐acetyl GO3 derived from hamster melanoma but not with 9‐O‐acetyl GD3 or human melanoma cells expressing 9‐O‐acetyl GD3 on their cell surface. In contrast, all O‐acetyl GD3 derivatives used for immunization were recognized by murine MAbs that reacted with 9‐O‐acetyl GD3, and immunization of mice with buttermilk‐derived O‐acetyl GD3 resulted in the production of antibodies that reacted with human melanoma cells expressing 9‐O‐acetyl GD3. Apparently, the human and murine immune systems preferentially recognize different epitopes on these molecules. © 1995 Wiley‐Liss, Inc.

AB - Gangliosides expressed in malignant melanoma are potential targets for immunotherapy. Immunization of melanoma patients with vaccines containing purified GM2 ganglioside has resulted in induction of GM2 antibodies, and high titers of GM2 antibodies have correlated with increased survival. Melanoma ganglioside 9‐O‐acetyl GD3 is another candidate for ganglioside vaccine construction because of its limited expression in normal human tissues. As purification of 9‐O‐acetyl GD3 from human melanoma (9‐O‐acetylated on the terminal sialic acid) is not practical for broad application, we investigated the antibody response of melanoma patients to O‐acetyl GD3 from several additional sources: hamster melanoma (7‐O‐acetyl GO3), bovine buttermilk (mixture of 7‐O‐acetyl GD3, 9‐O‐acetyl GD3 and 7,9‐di‐O‐acetyl GD3) and chemically modified GD3 from bovine brain (9‐O‐acetylated on the subterminal sialic acid). Only immunization with the buttermilk‐derived O‐acetyl GD3 preparation resulted in consistent production of IgM antibodies. However, the induced antibodies reacted with the immunogen and with 7‐O‐acetyl GO3 derived from hamster melanoma but not with 9‐O‐acetyl GD3 or human melanoma cells expressing 9‐O‐acetyl GD3 on their cell surface. In contrast, all O‐acetyl GD3 derivatives used for immunization were recognized by murine MAbs that reacted with 9‐O‐acetyl GD3, and immunization of mice with buttermilk‐derived O‐acetyl GD3 resulted in the production of antibodies that reacted with human melanoma cells expressing 9‐O‐acetyl GD3. Apparently, the human and murine immune systems preferentially recognize different epitopes on these molecules. © 1995 Wiley‐Liss, Inc.

UR - http://www.scopus.com/inward/record.url?scp=0029131343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029131343&partnerID=8YFLogxK

U2 - 10.1002/ijc.2910620604

DO - 10.1002/ijc.2910620604

M3 - Article

C2 - 7558412

AN - SCOPUS:0029131343

VL - 62

SP - 668

EP - 672

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 6

ER -